These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34074570)

  • 1. Serum sclerostin in acute kidney injury patients.
    Fayed A; Abdulazim DO; Amin M; Elhadidy S; Samir HH; Salem MM; Abd ElAzim IM; El Hawary KES; Sharaf El Din UA;
    Nefrologia (Engl Ed); 2021 May; ():. PubMed ID: 34074570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum sclerostin in acute kidney injury patients.
    Fayed A; Abdulazim DO; Amin M; Elhadidy S; Samir HH; Salem MM; Abd ElAzim IM; El Hawary KES; Sharaf El Din UA;
    Nefrologia (Engl Ed); 2022; 42(1):50-55. PubMed ID: 36153899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor-23 is a strong predictor of insulin resistance among chronic kidney disease patients.
    Fayed A; El Nokeety MM; Heikal AA; Abdulazim DO; Naguib MM; Sharaf El Din UAA;
    Ren Fail; 2018 Nov; 40(1):226-230. PubMed ID: 29619868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of FGF-23 With Biochemical Markers and Bone Density in Chronic Kidney Disease-Bone Mineral Density Disorder.
    Hussain I; Tandi R; Singh G; Kaur G; Abhishek ; Dodda S; Patel D; Natarajan B; Maram T; Kedia A; Vempati R; Sahu S; Choubey U
    Cureus; 2023 Jan; 15(1):e33879. PubMed ID: 36812096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity.
    Grethen E; Hill KM; Jones R; Cacucci BM; Gupta CE; Acton A; Considine RV; Peacock M
    J Clin Endocrinol Metab; 2012 May; 97(5):1655-62. PubMed ID: 22362819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD.
    Behets GJ; Viaene L; Meijers B; Blocki F; Brandenburg VM; Verhulst A; D'Haese PC; Evenepoel P
    PLoS One; 2017; 12(5):e0176411. PubMed ID: 28493902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of hepatitis virus infection on arterial calcification among incident hemodialysis patients.
    Fayed A; Soliman A; El Mahdy H; Hamza W; Abdulazim DO; Salem MM; Sharaf El Din UA;
    Nefrologia (Engl Ed); 2020; 40(3):336-344. PubMed ID: 31864861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of Calcium Homeostasis in Acute Kidney Injury: A Prospective Observational Study.
    Singh NP; Panwar V; Aggarwal NP; Chhabra SK; Gupta AK; Ganguli A
    Indian J Crit Care Med; 2022 Mar; 26(3):302-306. PubMed ID: 35519919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Circulating bone turnover markers and their relationships in hemodialysis patients with vitamin D deficiency].
    Kulicki P; Żebrowski P; Sokalski A; Klatko W; Birecka M; Mieczkowski M; Niemczyk S; Małyszko J; Matuszkiewicz-Rowińska J
    Wiad Lek; 2019; 72(11 cz 2):2202-2209. PubMed ID: 31860837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial.
    Triwatana W; Satirapoj B; Supasyndh O; Nata N
    Int Urol Nephrol; 2023 May; 55(5):1255-1262. PubMed ID: 36441433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder?
    Figurek A; Spasovski G
    Int Urol Nephrol; 2018 Oct; 50(10):1863-1870. PubMed ID: 30030677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between the levels of sclerostin, phosphate, and fibroblast growth factor-23 and treatment with vitamin D in hemodialysis patients with low intact PTH level.
    Asamiya Y; Yajima A; Shimizu S; Otsubo S; Tsuchiya K; Nitta K
    Osteoporos Int; 2015 Mar; 26(3):1017-28. PubMed ID: 25366373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.
    Sánchez Fructuoso AI; Maestro ML; Calvo N; De La Orden V; Pérez Flores I; Vidaurreta M; Valero R; Fernández-Pérez C; Barrientos A
    Transplant Proc; 2012 Nov; 44(9):2551-4. PubMed ID: 23146451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease.
    Stubbs JR; He N; Idiculla A; Gillihan R; Liu S; David V; Hong Y; Quarles LD
    J Bone Miner Res; 2012 Jan; 27(1):38-46. PubMed ID: 22031097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parathyroid Hormone Regulates Circulating Levels of Sclerostin and FGF23 in a Primary Hyperparathyroidism Model.
    Nagata Y; Imanishi Y; Tateishi T; Miyaoka D; Kurajoh M; Arnold A; Emoto M
    J Endocr Soc; 2022 Apr; 6(4):bvac027. PubMed ID: 35284773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Varying Patterns of Biomarkers of Mineral and Bone Metabolism After Kidney Transplantation.
    Makówka A; Głyda M; Majewska ER; Nowicki M
    Horm Metab Res; 2017 Aug; 49(8):618-624. PubMed ID: 28679143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.
    Kanda E; Yoshida M; Sasaki S
    BMC Nephrol; 2012 Sep; 13():122. PubMed ID: 23013306
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.